Brokerages Set HilleVax, Inc. (NASDAQ:HLVX) Target Price at $3.00

HilleVax, Inc. (NASDAQ:HLVX) has been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold rating. The average 1-year target price among brokerages that have covered the stock in the last year is $3.00.

Separately, HC Wainwright reiterated a “neutral” rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, March 31st.

Hedge Funds Weigh In On HilleVax

A number of hedge funds have recently modified their holdings of HLVX. Jane Street Group LLC grew its position in HilleVax by 81.7% during the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after purchasing an additional 35,546 shares during the last quarter. Barclays PLC grew its holdings in shares of HilleVax by 255.6% during the third quarter. Barclays PLC now owns 42,033 shares of the company’s stock worth $74,000 after buying an additional 30,213 shares during the last quarter. SG Americas Securities LLC increased its position in HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock valued at $38,000 after acquiring an additional 6,916 shares during the period. Ieq Capital LLC raised its stake in HilleVax by 71.1% during the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock valued at $47,000 after acquiring an additional 9,344 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in HilleVax during the 4th quarter worth approximately $26,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Stock Performance

HLVX opened at $1.93 on Friday. HilleVax has a one year low of $1.34 and a one year high of $16.31. The company has a market cap of $96.77 million, a P/E ratio of -0.62 and a beta of 0.86. The business’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $1.84.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). As a group, analysts predict that HilleVax will post -2.64 earnings per share for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.